Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
panobinostat
Class :
histone deacetylase (HDAC) inhibitors, Antineoplastics, Pan-Deacetylase Inhibitors
Brand Name :
No Data Available.
Synonyms :
panobinostat
Class :
histone deacetylase (HDAC) inhibitors, Antineoplastics, Pan-Deacetylase Inhibitors
Dosage forms & Strengths
Capsule, Oral:
10 mg
15 mg
20 mg
Note:
Approval of Panobinostat for the treatment of multiple myeloma in the US market has been withdrawn by the manufacturer.
Single agent:
20
mg
Orally 
once a day
for every other day of the week (total duration 21-day).
Combination regimen: 20 mg once a day for 8 cycles in combination with bortezomib and dexamethasone.
Take the missed dose 12 Hr after the scheduled time.
Do not repeat the dose if vomiting occurs; continue with the next scheduled dose.
Dose Adjustments
Hepatic impairment: Mild hepatic impairment: reduce the dose to 15 mg once a day and monitor the symptoms.
Moderate hepatic impairment: reduce the dose to 10 mg once a day and monitor for adverse effects.
Severe hepatic impairment: Terminate the use.
Hematologic toxicity: For Grade 4 (platelets < 25,000/mm3 with bleeding), ANC 500 to 750/mm3, and Anemia: Terminate the treatment temporarily, monitor symptoms, and resume at a lower dose
Nonhematologic toxicity: Cardiovascular: QTcF > 480 msec: Terminate the use of Panobinostat.
Diarrhea, abdominal cramping, loose stools, and nausea/vomiting: start antidiarrheal medication such as loperamide.
safety and efficacy not established
refer adult dosing
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
When nafcillin combines with panobinostat, nafcillin will decrease the effect of action of panobinostat by affecting enzyme CYP3A4 metabolism.
QTc interval increases on taking panobinostat and lenvatinib together. Avoid or take an alternate drug.
when both drugs are combined, both increase the QTC interval  
both lapatinib and panobinostat increase the QTc interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of panobinostat 
when used together, entrectinib and panobinostat both increase the QTc interval
when used together, encorafenib and panobinostat both increase the QTc interval
may have an increasingly adverse effect when combined with taurursodiol
panobinostat: they may enhance the serum concentration of CYP3A4 Inhibitors
panobinostat: they may enhance the serum concentration of CYP3A4 Inhibitors
panobinostat: they may enhance the serum concentration of CYP3A4 Inhibitors
panobinostat: they may enhance the serum concentration of CYP3A4 Inhibitors
panobinostat: they may enhance the serum concentration of CYP3A4 Inhibitors
when both drugs are combined, there may be an increased risk or severity of adverse effects  
the effect of panobinostat is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
granisetron increases the effect of arrhythmia of panobinostat
Frequency defined
> 10%
Decreased weight
Hyperbilirubinemia
Hypermagnesemia
Decreased appetite
Hyperphosphatemia
Hypocalcemia
Pregnancy consideration:
US FDA pregnancy category: Not Assigned
Breastfeeding warnings:
Excreted into human milk is Unknown.
Pregnancy category:
Category A:Â well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D:Â adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Patient information leaflet
Generic Name: panobinostat
Why do we use panobinostat?
panobinostat belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. It is primarily used in the treatment of certain types of cancer, particularly multiple myeloma.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
